Terai Yuri Laguna, Huang Chun, Wang Baoli, Kang Xiaonan, Han Jing, Douglass Jacqueline, Hsiue Emily Han-Chung, Zhang Ming, Purohit Raj, deSilva Taylor, Wang Qing
Complete Omics Inc., Baltimore, MD 21227, USA.
Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Cancers (Basel). 2022 Feb 28;14(5):1243. doi: 10.3390/cancers14051243.
The presentation of neoantigens on the cell membrane is the foundation for most cancer immunotherapies. Due to their extremely low abundance, analyzing neoantigens in clinical samples is technically difficult, hindering the development of neoantigen-based therapeutics for more general use in the treatment of diverse cancers worldwide. Here, we describe an integrated system, "Valid-NEO", which reveals patient-specific cancer neoantigen therapeutic targets from minute amounts of clinical samples through direct observation, without computer-based prediction, in a sensitive, rapid, and reproducible manner. The overall four-hour procedure involves mass spectrometry analysis of neoantigens purified from tumor samples through recovery of HLA molecules with HLA antibodies. Valid-NEO could be applicable to the identification and quantification of presented neoantigens in cancer patients, particularly when only limited amounts of sample are available.
细胞膜上新抗原的呈递是大多数癌症免疫疗法的基础。由于其丰度极低，在临床样本中分析新抗原在技术上具有挑战性，这阻碍了基于新抗原的疗法在全球范围内更广泛地用于治疗各种癌症的发展。在此，我们描述了一个集成系统“Valid-NEO”，它能够以灵敏、快速且可重复的方式，通过直接观察，而非基于计算机的预测，从微量临床样本中揭示患者特异性的癌症新抗原治疗靶点。整个四小时的流程包括通过用HLA抗体回收HLA分子，对从肿瘤样本中纯化的新抗原进行质谱分析。Valid-NEO可应用于癌症患者中呈递的新抗原的鉴定和定量，特别是在仅有有限量样本可用的情况下。
Zotero 插件